Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010402011> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2010402011 endingPage "786" @default.
- W2010402011 startingPage "785" @default.
- W2010402011 abstract "Advances in cancer therapies have brought about changes in the treatment of metastatic prostate cancer. Because prostate cancer usually metastasises to the bone, 1 Carlin BI Andriole GL The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000; 88: 2989-2994 Crossref PubMed Google Scholar strategies to target the bone are being actively developed (panel). Zoledronic acid was the first approved agent for retarding skeletal events in men with metastatic prostate cancer, on the basis of the phase 3 trial 2 Saad F Gleason DM Murray R et al. for the Zoledronic Acid Prostate Cancer Study GroupA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458-1468 Crossref PubMed Scopus (1449) Google Scholar showing that it was superior to placebo. Since then, this drug has become a standard adjunctive treatment for men with prostate cancer with bone metastases. PanelTherapeutic strategies targeting bone signalling and metastases in prostate cancerTargeting bone-forming osteoblasts •Bone-seeking radiopharmaceuticals (samarium-153, strontium-89) •Inhibition of endothelin axis (ZD4054) •Targeting insulin-like growth factor (IGF) axis •Targeting transforming growth factor (TGF) axis, Wnt signalling, and bone morphogenic proteins (BMP) pathways Targeting bone-resorptive osteoclasts •Bisphosphonates (zoledronic acid) •Inhibition of receptor activator of nuclear factor κ-B ligand (RANKL; denosumab) •Inhibition of osteoclast function (cathepsins, Src homology 2 inhibitors, interleukin-6 inhibitors) Targeting bone-forming osteoblasts •Bone-seeking radiopharmaceuticals (samarium-153, strontium-89) •Inhibition of endothelin axis (ZD4054) •Targeting insulin-like growth factor (IGF) axis •Targeting transforming growth factor (TGF) axis, Wnt signalling, and bone morphogenic proteins (BMP) pathways Targeting bone-resorptive osteoclasts •Bisphosphonates (zoledronic acid) •Inhibition of receptor activator of nuclear factor κ-B ligand (RANKL; denosumab) •Inhibition of osteoclast function (cathepsins, Src homology 2 inhibitors, interleukin-6 inhibitors) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyDenosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer. Full-Text PDF" @default.
- W2010402011 created "2016-06-24" @default.
- W2010402011 creator A5036848171 @default.
- W2010402011 date "2011-03-01" @default.
- W2010402011 modified "2023-09-26" @default.
- W2010402011 title "Unravelling the role of denosumab in prostate cancer" @default.
- W2010402011 cites W1974425256 @default.
- W2010402011 cites W1992053982 @default.
- W2010402011 cites W2066845679 @default.
- W2010402011 cites W2093252878 @default.
- W2010402011 cites W2103904089 @default.
- W2010402011 cites W2109361037 @default.
- W2010402011 cites W2137302084 @default.
- W2010402011 cites W2607028219 @default.
- W2010402011 doi "https://doi.org/10.1016/s0140-6736(11)60100-1" @default.
- W2010402011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21353698" @default.
- W2010402011 hasPublicationYear "2011" @default.
- W2010402011 type Work @default.
- W2010402011 sameAs 2010402011 @default.
- W2010402011 citedByCount "13" @default.
- W2010402011 countsByYear W20104020112012 @default.
- W2010402011 countsByYear W20104020112013 @default.
- W2010402011 countsByYear W20104020112014 @default.
- W2010402011 countsByYear W20104020112016 @default.
- W2010402011 countsByYear W20104020112017 @default.
- W2010402011 countsByYear W20104020112019 @default.
- W2010402011 crossrefType "journal-article" @default.
- W2010402011 hasAuthorship W2010402011A5036848171 @default.
- W2010402011 hasConcept C121608353 @default.
- W2010402011 hasConcept C126322002 @default.
- W2010402011 hasConcept C134018914 @default.
- W2010402011 hasConcept C143998085 @default.
- W2010402011 hasConcept C170493617 @default.
- W2010402011 hasConcept C2776033226 @default.
- W2010402011 hasConcept C2776286101 @default.
- W2010402011 hasConcept C2776326535 @default.
- W2010402011 hasConcept C2776541429 @default.
- W2010402011 hasConcept C2777783956 @default.
- W2010402011 hasConcept C2780192828 @default.
- W2010402011 hasConcept C2780426850 @default.
- W2010402011 hasConcept C502942594 @default.
- W2010402011 hasConcept C673006 @default.
- W2010402011 hasConcept C71924100 @default.
- W2010402011 hasConcept C88045685 @default.
- W2010402011 hasConceptScore W2010402011C121608353 @default.
- W2010402011 hasConceptScore W2010402011C126322002 @default.
- W2010402011 hasConceptScore W2010402011C134018914 @default.
- W2010402011 hasConceptScore W2010402011C143998085 @default.
- W2010402011 hasConceptScore W2010402011C170493617 @default.
- W2010402011 hasConceptScore W2010402011C2776033226 @default.
- W2010402011 hasConceptScore W2010402011C2776286101 @default.
- W2010402011 hasConceptScore W2010402011C2776326535 @default.
- W2010402011 hasConceptScore W2010402011C2776541429 @default.
- W2010402011 hasConceptScore W2010402011C2777783956 @default.
- W2010402011 hasConceptScore W2010402011C2780192828 @default.
- W2010402011 hasConceptScore W2010402011C2780426850 @default.
- W2010402011 hasConceptScore W2010402011C502942594 @default.
- W2010402011 hasConceptScore W2010402011C673006 @default.
- W2010402011 hasConceptScore W2010402011C71924100 @default.
- W2010402011 hasConceptScore W2010402011C88045685 @default.
- W2010402011 hasIssue "9768" @default.
- W2010402011 hasLocation W20104020111 @default.
- W2010402011 hasLocation W20104020112 @default.
- W2010402011 hasOpenAccess W2010402011 @default.
- W2010402011 hasPrimaryLocation W20104020111 @default.
- W2010402011 hasRelatedWork W118203831 @default.
- W2010402011 hasRelatedWork W1971173343 @default.
- W2010402011 hasRelatedWork W1974283015 @default.
- W2010402011 hasRelatedWork W1981266896 @default.
- W2010402011 hasRelatedWork W2124998345 @default.
- W2010402011 hasRelatedWork W2133920343 @default.
- W2010402011 hasRelatedWork W2339278859 @default.
- W2010402011 hasRelatedWork W2417724487 @default.
- W2010402011 hasRelatedWork W4362596878 @default.
- W2010402011 hasRelatedWork W2773216875 @default.
- W2010402011 hasVolume "377" @default.
- W2010402011 isParatext "false" @default.
- W2010402011 isRetracted "false" @default.
- W2010402011 magId "2010402011" @default.
- W2010402011 workType "article" @default.